Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.

Literature DB >> 24671322

Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.

Ann-Sophie Lauenstein¹, Mark Stettner, Bernd C Kieseier, Eckart Lensch.

Abstract

We present a 32-year-old female patient with fulminant neuromyelitis optica. After the initial treatment with the monoclonal antibody rituximab failed, therapy with the anti-IL-6 receptor antagonist tocilizumab was initiated. The patient experienced a clinically relevant improvement from severe tetraparesis to low-grade paresis, which is still maintained. On MRI of the spinal cord an almost complete restitution of a predescribed extensive myelopathy accompanied this clinical improvement. Meanwhile clinical stability was achieved for over 1 year without any side effects of the ongoing treatment with tocilizumab.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24671322 PMCID： PMC3975485 DOI： 10.1136/bcr-2013-202939

Source DB: PubMed Journal: BMJ Case Rep ISSN： 1757-790X

15 in total

1. Treatment of neuromyelitis optica: current debate.

Authors: Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal: Ther Adv Neurol Disord Date: 2008-07 Impact factor: 6.570

2. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis.

Authors: Yuko Shimizu; Kazumasa Yokoyama; Tatsuro Misu; Toshiyuki Takahashi; Kazuo Fujihara; Seiji Kikuchi; Yasuto Itoyama; Makoto Iwata
Journal: J Neurol Date: 2007-11-21 Impact factor: 4.849

3. Does natalizumab therapy worsen neuromyelitis optica?

Authors: Anu Jacob; Michael Hutchinson; Liene Elsone; Siobhan Kelly; Rehiana Ali; Ivars Saukans; Niall Tubridy; Mike Boggild
Journal: Neurology Date: 2012-08-22 Impact factor: 9.910

4. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

Authors: Bianca Weinstock-Guttman; Murali Ramanathan; Norah Lincoff; Salvatore Q Napoli; Jitendra Sharma; Joan Feichter; Rohit Bakshi
Journal: Arch Neurol Date: 2006-07

5. An open label study of the effects of rituximab in neuromyelitis optica.

Authors: B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal: Neurology Date: 2005-04-12 Impact factor: 9.910

6. Revised diagnostic criteria for neuromyelitis optica.

Authors: D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal: Neurology Date: 2006-05-23 Impact factor: 9.910

7. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Authors: Norio Chihara; Toshimasa Aranami; Wakiro Sato; Yusei Miyazaki; Sachiko Miyake; Tomoko Okamoto; Masafumi Ogawa; Tatsushi Toda; Takashi Yamamura
Journal: Proc Natl Acad Sci U S A Date: 2011-02-14 Impact factor: 11.205

Review 8. Tocilizumab.

Authors: Adith Venkiteshwaran
Journal: MAbs Date: 2009-09-10 Impact factor: 5.857

9. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE.

Authors: Veit Rothhammer; Sylvia Heink; Franziska Petermann; Rajneesh Srivastava; Malte C Claussen; Bernhard Hemmer; Thomas Korn
Journal: J Exp Med Date: 2011-10-24 Impact factor: 14.307

10. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab.

Authors: Manabu Araki; Toshimasa Aranami; Takako Matsuoka; Masakazu Nakamura; Sachiko Miyake; Takashi Yamamura
Journal: Mod Rheumatol Date: 2012-07-11 Impact factor: 3.023

6 in total

Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.

1. Treatment of neuromyelitis optica: current debate.

2. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis.

3. Does natalizumab therapy worsen neuromyelitis optica?

4. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

5. An open label study of the effects of rituximab in neuromyelitis optica.

6. Revised diagnostic criteria for neuromyelitis optica.

7. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Review 8. Tocilizumab.

9. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE.

10. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab.

Review 1. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Review 2. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Review 3. What's new in neuromyelitis optica? A short review for the clinical neurologist.

4. An Update on the Treatment of Pediatric Autoimmune Encephalitis.

5. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Review 6. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.